SG11202101824VA - Platform assembly process for drug delivery device - Google Patents

Platform assembly process for drug delivery device

Info

Publication number
SG11202101824VA
SG11202101824VA SG11202101824VA SG11202101824VA SG11202101824VA SG 11202101824V A SG11202101824V A SG 11202101824VA SG 11202101824V A SG11202101824V A SG 11202101824VA SG 11202101824V A SG11202101824V A SG 11202101824VA SG 11202101824V A SG11202101824V A SG 11202101824VA
Authority
SG
Singapore
Prior art keywords
delivery device
drug delivery
assembly process
platform assembly
platform
Prior art date
Application number
SG11202101824VA
Inventor
Jakob Pedersen
Matias Melander
Christian Plambech
Adam Mccullough
Rasmus Ohlenschlager
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11202101824VA publication Critical patent/SG11202101824VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/1413—Modular systems comprising interconnecting elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2207/00—Methods of manufacture, assembly or production
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/49—Method of mechanical manufacture
    • Y10T29/49826—Assembling or joining
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/53—Means to assemble or disassemble
SG11202101824VA 2018-10-15 2019-10-15 Platform assembly process for drug delivery device SG11202101824VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745739P 2018-10-15 2018-10-15
PCT/US2019/056175 WO2020081480A1 (en) 2018-10-15 2019-10-15 Platform assembly process for drug delivery device

Publications (1)

Publication Number Publication Date
SG11202101824VA true SG11202101824VA (en) 2021-03-30

Family

ID=68425346

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101824VA SG11202101824VA (en) 2018-10-15 2019-10-15 Platform assembly process for drug delivery device

Country Status (14)

Country Link
US (1) US20210346596A1 (en)
EP (1) EP3866889A1 (en)
JP (1) JP2022504805A (en)
CN (1) CN112689523A (en)
AR (1) AR116703A1 (en)
AU (1) AU2019359801A1 (en)
CA (1) CA3109988A1 (en)
EA (1) EA202191038A1 (en)
IL (1) IL281895A (en)
MA (1) MA53913A (en)
MX (1) MX2021002791A (en)
SG (1) SG11202101824VA (en)
TW (1) TW202031306A (en)
WO (1) WO2020081480A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021219839A1 (en) 2020-02-13 2022-08-25 Amgen Inc. Formulations of human anti-TSLP antibodies and methods of treating inflammatory disease
US20230081261A1 (en) 2020-02-18 2023-03-16 Amgen Inc. Formulations of human anti-tslp antibodies and methods of using the same
TW202304980A (en) 2021-04-23 2023-02-01 美商安進公司 Modified anti-tslp antibodies
AU2022262421A1 (en) 2021-04-23 2023-10-19 Amgen Inc. Anti-tslp antibody compositions and uses thereof
WO2023016891A1 (en) * 2021-08-09 2023-02-16 Shl Medical Ag A method of manufacturing a sub-assembly of a medicament delivery device
GB2618850A (en) * 2022-05-20 2023-11-22 Tip Top Com Ltd A method of assembling a needle safety apparatus

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (en) 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
DE69534530T2 (en) 1994-08-12 2006-07-06 Immunomedics, Inc. FOR B-CELL LYMPHOMA AND LEUKEMIA SPECIMEN IMMUNOCONJUGATES AND HUMAN ANTIBODIES
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
JP2001510033A (en) 1997-07-14 2001-07-31 ボルダー バイオテクノロジー， インコーポレイテッド Derivatives of growth hormone and related proteins
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
KR100641969B1 (en) 1997-07-23 2006-11-06 로셰 디아그노스틱스 게엠베하 Production of erythropoietin by endogenous gene activation
US6030086A (en) 1998-03-02 2000-02-29 Becton, Dickinson And Company Flash tube reflector with arc guide
US6310078B1 (en) 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
CA2330527A1 (en) 1998-06-15 1999-12-23 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
ME00238B (en) 1998-10-23 2011-02-10 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
EP1813624B1 (en) 1998-10-23 2010-08-11 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
CN1333828B (en) 1998-11-27 2015-05-13 Ucb医药有限公司 Compositions and methods for increasing bone mineralization
EP1006184A1 (en) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
JP2002544123A (en) 1999-04-14 2002-12-24 スミスクライン・ビーチャム・コーポレイション Erythropoietin receptor antibody
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CZ299516B6 (en) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
WO2001031007A2 (en) 1999-10-22 2001-05-03 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2001036489A2 (en) 1999-11-12 2001-05-25 Merck Patent Gmbh Erythropoietin forms with improved properties
ATE282708T1 (en) 2000-01-21 2004-12-15 Biovex Ltd HERPES VIRUS STRAINS FOR GENE THERAPY
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
ATE395357T1 (en) 2000-04-21 2008-05-15 Amgen Inc METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING ANEMIA
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
CZ2003678A3 (en) 2000-09-08 2004-03-17 Gryphon Therapeutics, Inc. Erythropoiesis stimulating synthetic proteins
US7271689B1 (en) 2000-11-22 2007-09-18 Fonar Corporation Magnet structure
WO2002049673A2 (en) 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
CA2433800C (en) 2001-01-05 2016-09-13 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
IL158261A0 (en) 2001-04-04 2004-05-12 Genodyssee New polynucleotides and polypeptides of the erythropoietin gene
NZ529267A (en) 2001-05-11 2006-05-26 Amgen Inc Peptides and related molecules that bind to tall-1
TR201809008T4 (en) 2001-06-26 2018-07-23 Amgen Fremont Inc Antibodies against opgl.
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
EA014802B1 (en) 2001-08-23 2011-02-28 Генмаб А/С HUMAN ANTIBODIES SPECIFIC FOR INTERLEUKIN 15 (IL-15)\ (VARIANTS), A METHOD OF PRODUCING THEREOF, AN IMMUNOCONJUGATE BASED THEREON, A TRANSFECTOMA, A HYBRIDOMA, A TRANSGENIC ANIMAL, AN EXPRESSION VECTOR (VARIANTS) AND NUCLEIC ACID FOR PRODUCING THEREOF, A METHOD OF TREATMENT (VARIANTS) AND DIAGNOSING AN IL-15 MEDIATED DISEASE, A METHOD OF INHIBITING IL-15 INDUCED TNF-α, AND A METHOD OF INHIBITING INDUCED IL-15 CELL PROLIFERATION.
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
AU2002351746A1 (en) 2001-12-21 2003-07-15 Maxygen Aps Erythropoietin conjugates
EP1798242B1 (en) 2002-01-18 2013-01-23 Pierre Fabre Medicament Anti-IGF-IR antibodies and their applications
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
GB0202252D0 (en) 2002-01-31 2002-03-20 Oxford Biomedica Ltd Anemia
WO2003064664A1 (en) 2002-01-31 2003-08-07 Oxford Biomedica (Uk) Limited Physiologically regulated erythropoietin- exprressing vector for the treatment of anaemia
JP4109204B2 (en) 2002-03-26 2008-07-02 レツク・フアーマシユーテイカルズ・デー・デー Method for producing desired erythropoietin glycoisoform profile
EP1572079A4 (en) 2002-03-29 2006-09-06 Centocor Inc Mammalian cdr mimetibodies, compositions, methods and uses
ATE434662T1 (en) 2002-03-29 2009-07-15 Kumiai Chemical Industry Co ACETOLACTATE SYNTHASE CODING GENES
SE0201142D0 (en) 2002-04-16 2002-04-16 Pharmacia Ab A system and method for modification of a device and a device suitable for modification
CA2485365A1 (en) 2002-05-13 2003-11-20 Modigenetech Ltd. Ctp-extended erythropoietin
PL210412B1 (en) 2002-05-24 2012-01-31 Schering Corp Neutralizing human anti-igfr antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
BR0312276A (en) 2002-06-28 2005-04-26 Centocor Inc Mammalian epo ch1-removed mimetibodies, compositions, methods and uses
AU2003280130B2 (en) 2002-06-28 2009-06-11 Centocor, Inc. Mammalian CH1 deleted mimetibodies, compositions, methods and uses
AU2003246486A1 (en) 2002-07-19 2004-02-09 Cangene Corporation Pegylated erythropoietic compounds
AU2003254950A1 (en) 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
EP1572946B1 (en) 2002-09-06 2012-03-14 Amgen, Inc. Therapeutic human anti-il-1r1 monoclonal antibody
BR0314227A (en) 2002-09-11 2005-10-25 Fresenius Kabi De Gmbh Hydroxyalkyl Starch Derivatives
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
TWI320716B (en) 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
US20040071694A1 (en) 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
US7335743B2 (en) 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
KR20120060250A (en) 2002-12-20 2012-06-11 암겐 인코포레이티드 Binding agents which inhibit myostatin
MXPA05009837A (en) 2003-03-14 2005-12-05 Pharmacia Corp Antibodies to igf-i receptor for the treatment of cancers.
CA2519113C (en) 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EP2365001A3 (en) 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EA010099B1 (en) 2003-05-12 2008-06-30 Афимакс, Инк. Novel peptides that bind to the erythropoietin receptor and methods for use thereof
ES2323465T3 (en) 2003-05-12 2009-07-16 Affymax, Inc. NOVELTY PEPTIDES THAT JOIN THE Erythropoietin Receptor.
CA2525464A1 (en) 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
MXPA05012936A (en) 2003-05-30 2006-05-17 Johnson & Johnson Formation of novel erythropoietin conjugates using transglutaminase.
WO2005001136A1 (en) 2003-06-04 2005-01-06 Irm Llc Methods and compositions for modulating erythropoietin expression
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
JP4489077B2 (en) 2003-07-15 2010-06-23 アムジェン インコーポレイテッド Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
MEP31408A (en) 2003-07-18 2010-10-10 Abgenix Inc Specific binding agents to hepatocyte growth factor
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2005021579A2 (en) 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Epo mimetic peptides and fusion proteins
CN1882355A (en) 2003-09-09 2006-12-20 沃伦药品公司 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
UA89481C2 (en) 2003-09-30 2010-02-10 Центокор, Инк. Human epo mimetic hinge core mimetibodies, compositions, methods and uses
AU2004316266A1 (en) 2003-09-30 2005-09-09 Centocor, Inc. Human hinge core mimetibodies, compositions, methods and uses
KR101225463B1 (en) 2003-11-07 2013-01-24 임뮤넥스 코포레이션 Antibodies that bind interleukin-4 receptor
PE20050928A1 (en) 2003-11-21 2005-11-08 Schering Corp THERAPEUTIC COMBINATIONS OF ANTI-IGFR1 ANTIBODY
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
NZ547168A (en) 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
EP1548031A1 (en) 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Nature-identical erythropoietin
EP1699920A4 (en) 2003-12-31 2008-05-28 Centocor Inc Novel recombinant proteins with n-terminal free thiol
PT1699821E (en) 2003-12-31 2012-08-23 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US7423139B2 (en) 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
WO2005070451A1 (en) 2004-01-22 2005-08-04 Zafena Aktiebolag Pharmaceutical composition comprising non-glycosylated erythropoietin
WO2005084711A1 (en) 2004-03-02 2005-09-15 Chengdu Institute Of Biological Products A pegylated recombinant erythropoietin that has in vivo activity
EP1758608A2 (en) 2004-03-11 2007-03-07 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyethyl starch and erythropoietin
US20060002929A1 (en) 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20080194475A1 (en) 2004-04-23 2008-08-14 Andrew Buchanan Erythropoietin Protein Variants
PL1781697T3 (en) 2004-07-07 2009-10-30 H Lundbeck As Novel carbamylated epo and method for its production
FR2873699B1 (en) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF
WO2006029094A2 (en) 2004-09-02 2006-03-16 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
WO2006050959A2 (en) 2004-11-10 2006-05-18 Aplagen Gmbh Molecules which promote hematopoiesis
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
DK2100618T3 (en) 2005-06-17 2014-03-03 Imclone Llc Anti-PDGFR alpha antibody for use in the treatment of metastatic bone cancer
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
UA102667C2 (en) 2005-07-18 2013-08-12 Емджен Інк. Human neutralizing anti b7rp1 antibody
FR2888850B1 (en) 2005-07-22 2013-01-11 Pf Medicament NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
PE20071101A1 (en) 2005-08-31 2007-12-21 Amgen Inc POLYPEPTIDES AND ANTIBODIES
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
EP2032600A2 (en) 2006-05-19 2009-03-11 Glycofi, Inc. Erythropoietin compositions
CL2007002567A1 (en) 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
EP2083861A4 (en) 2006-11-07 2010-11-24 Merck Sharp & Dohme Antagonists of pcsk9
EP2083859A4 (en) 2006-11-07 2010-11-24 Merck Sharp & Dohme Antagonists of pcsk9
US20100040610A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
CA2667869A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
AR064333A1 (en) 2006-12-14 2009-04-01 Schering Corp ANTI-TSLP DESIGN ANTIBODY
EP2137218A2 (en) 2007-04-13 2009-12-30 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
AU2008265128A1 (en) 2007-06-20 2008-12-24 Irm Llc Methods and compositions for treating allergic diseases
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
BRPI0818765A8 (en) 2007-10-26 2016-02-10 Schering Corp POLYPEPTIDE, ANTIBODY OR ITS ANTIGEN BINDING FRAGMENT, POLYNUCLEOTIDE, HOST CELL, VECTOR, COMPOSITION, USE AND METHOD FOR PRODUCING POLYPEPTIDE
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
TWI445716B (en) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Pcsk9 antagonists
JO3672B1 (en) 2008-12-15 2020-08-27 Regeneron Pharma High Affinity Human Antibodies to PCSK9
JO3382B1 (en) 2008-12-23 2019-03-13 Amgen Inc Human cgrp receptor binding antibodies
EP2480576A4 (en) 2009-09-25 2013-04-10 Merck Sharp & Dohme Antagonists of pcsk9
CA2777698A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
IN2012DN03824A (en) 2009-10-30 2015-08-28 Merck Sharp & Dohme
AR079336A1 (en) 2009-12-11 2012-01-18 Irm Llc ANTAGONISTS OF THE PRO-PROTEIN CONVERTASE-SUBTILISINE / TYPE 9 QUEXINE (PCSK9)
MX2012010481A (en) 2010-03-11 2012-10-09 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING.
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
GB2486693B (en) * 2010-12-22 2016-05-18 Owen Mumford Ltd Autoinjectors and manufacturing systems thereof
KR20130118925A (en) 2010-12-22 2013-10-30 제넨테크, 인크. Anti-pcsk9 antibodies and methods of use
AR084938A1 (en) 2011-01-28 2013-07-10 Sanofi Sa HUMAN ANTIBODIES AGAINST PROPROTEIN CONVERTASA SUBTILISINA / KEXINA TYPE 9 (ANTI PCSK9) FOR USE IN METHODS TO TREAT PATIENT GROUPS
EP2673302A1 (en) 2011-02-11 2013-12-18 Irm Llc Pcsk9 antagonists
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
JP5973228B2 (en) * 2012-05-11 2016-08-23 株式会社ダイセル Syringe
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
US20140274874A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
MX2015012891A (en) 2013-03-14 2015-12-03 Amgen Inc Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods.
JP6720167B2 (en) * 2014-11-12 2020-07-08 ノボ・ノルデイスク・エー／エス Method of manufacturing one of a range of auto-injectors
JP6531298B2 (en) * 2015-04-24 2019-06-19 エス・ハー・エル・メディカル・アクチェンゲゼルシャフトＳｈｌ Ｍｅｄｉｃａｌ Ａｇ Drug delivery device subassembly and drug delivery device
TW201700117A (en) 2015-06-03 2017-01-01 賽諾菲阿凡提斯德意志有限公司 Syringe carrier for an autoinjector and method of assembling

Also Published As

Publication number Publication date
AR116703A1 (en) 2021-06-02
AU2019359801A1 (en) 2021-03-18
US20210346596A1 (en) 2021-11-11
CN112689523A (en) 2021-04-20
MX2021002791A (en) 2021-05-12
TW202031306A (en) 2020-09-01
EA202191038A1 (en) 2021-07-06
CA3109988A1 (en) 2020-04-23
JP2022504805A (en) 2022-01-13
IL281895A (en) 2021-05-31
EP3866889A1 (en) 2021-08-25
WO2020081480A1 (en) 2020-04-23
MA53913A (en) 2022-01-19

Similar Documents

Publication Publication Date Title
CA186677S (en) Drug delivery device
IL273637A (en) Plungers for drug delivery devices
IL278782A (en) Automatic drug delivery device
IL291155A (en) Drug delivery device
IL291004A (en) Drug delivery device
FI3886944T3 (en) Drug delivery device
PL3684447T3 (en) Accessory device for drug delivery device
IL281895A (en) Platform assembly process for drug delivery device
IL291415A (en) Drug delivery device
IL291295A (en) Drug delivery device
EP3720522C0 (en) Drug delivery device
IL279127A (en) Delivery devices for administering drugs
EP3419695A4 (en) Compact platform for accurate drug delivery
IL291154A (en) Drug delivery device
GB201807040D0 (en) Drug delivery
IL280178A (en) System for a drug delivery device
IL275250A (en) Delivery device for drug pellets
GB2576808B (en) Medicament delivery device
GB201908810D0 (en) Delivery device for drug pellets
GB201607778D0 (en) Drug delivery device
GB2572137B (en) Delivery apparatus
IL280184A (en) Drug delivery devices
IL279811A (en) Activation mechanism for drug delivery device
GB201520653D0 (en) Apparatus for medicament delivery
SG11202005291WA (en) Priming system for drug delivery device